Betop Zhongchuang Invests RMB 30 Million in Biosyngen to Advance Its CAR-T Pipeline

PA3-17 Injection is the world's first IND-approved autologous CAR-T cell therapy candidate targeting CD7, aimed at T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL) after failure of second-line treatment. It innovatively adopts a non-gene-editing strategy, effectively addressing industry challenges such as CAR-T cell fratricide and tumor cell contamination during the preparation of PA3-17 Injection, and has established a brand-new quality control system.

In the Phase I registered clinical trial, the PA3-17 injection has demonstrated encouraging efficacy: the objective response rate (ORR) was 85%, and the MRD-negative complete remission rate reached 95%. Currently, the PA3-17 injection has been included in the list of breakthrough therapies and has entered the pivotal Phase II clinical trial stage, with the market launch process entering the "final countdown."

In addition, Bo sheng ji medicine science and technology (suzhou) co., LTD has also made new progress recently. In October this year, LV009 Injection, an in-vivo cell therapy product independently developed by the company, completed the first patient dosing. This marks that the CAR-T/NK technology of Bo sheng ji has officially stepped from "ex-vivo customization" into a new era of "in-vivo generation."

This candidate product, through breakthrough lentiviral vector technology, achieves highly efficient transfection of resting T cells and NK cells. It can simultaneously generate CD19-targeted CAR-T and CAR-NK cells, enabling synergistic attacks on tumor cells by both adaptive and innate immunity.

In the same month, the breakthrough research results of UTAA91, a universal cell candidate drug independently developed by Bo sheng ji medicine science and technology (suzhou) co., LTD, were selected for poster presentation at the 2025 American College of Rheumatology (ACR) Annual Meeting. UTAA91 is the world's first PD-1/CD19 dual-target universal CAR-Vδ1T cell therapy, capable of precisely targeting pathogenic T cells, efficiently eliminating B cells, and demonstrating superior tissue infiltration. In preclinical studies, UTAA91 showed good precision targeting ability, achieving synergistic blockade of the T-B cell bidirectional pathogenic pathways, and possesses clinical translational potential.